SNPMiner Trials by Shray Alag


SNPMiner SNPMiner Trials (Home Page)


Report for Clinical Trial NCT01015963

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

A Study of the Docetaxel Pharmacodynamics and Polymorphisms in ABCC2 and SLC01B3 in Caucasian and African-American Cancer Patients

This research trial studies deoxyribonucleic acid (DNA) in blood samples from Caucasian and African-American cancer patients who received docetaxel on clinical trial CLB-9871. Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors learn more about how docetaxel is used by the body.

NCT01015963 Bladder Cancer Breast Cancer Head and Neck Cancer Lung Cancer Unspecified Adult Solid Tumor, Protocol Specific
MeSH:Breast Neoplasms Lung Neoplasms Head and Neck Neoplasms Urinary Bladder Neoplasms
HPO:Bladder neoplasm Breast carcinoma Neoplasm of head and neck Neoplasm of the breast Neoplasm of the lung

1 Interventions

Name: laboratory biomarker analysis

Description: Perform DNA sample analysis
Type: Other
Group Labels: 1

Ancillary-correlative (DNA sample analysis)


Primary Outcomes

Measure: Incidence of ABBC2 polymorphism (rs12762549) and a SLC01B3 polymorphism (rs11045585) with docetaxel exposure

Time: Up to 2 years

Measure: Incidence of SLC01B3 polymorphism (rs11045585)

Time: Up to 2 years

Secondary Outcomes

Measure: Incidence of grade III/IV leukopenia/neutropenia (induced by docetaxel)

Time: Up to 2 years

Time Perspective: Retrospective

Case-Only


There are 2 SNPs

SNPs


1 rs11045585

Incidence of ABBC2 polymorphism (rs12762549) and a SLC01B3 polymorphism (rs11045585) with docetaxel exposure.

Incidence of SLC01B3 polymorphism (rs11045585).


2 rs12762549

Incidence of ABBC2 polymorphism (rs12762549) and a SLC01B3 polymorphism (rs11045585) with docetaxel exposure.



HPO Nodes


HPO: